Venus Remedies

US FDA Grants Qualified Infectious Disease Product Designation to Venus Remedies’ VRP-034, a Novel Polymyxin B Formulation

VRP-034 is a novel supramolecular cationic (SMC) formulation of polymyxin B sulphate, uniquely developed to mitigate the nephrotoxic effects associated with conventional polymyxin B (PMB) therapy Key preclinical findings for VRP-034 included up to 70% reduction in nephrotoxicity compared to marketed PMB The QIDP designation by the United States Food and Drug Administration (US FDA)...

Venus Remedies gets Marketing Authorization for anticoagulant ‘Enoxaparin’ from Indonesia

Latest approvals from Indonesia, Southeast Asia’s largest pharma market, to help strengthen company’s regional and global aspirations 10 February 2025 -- Panchkula, India -- Venus Remedies Limited, a leading Indian exporter of generic drugs, has received marketing authorization from Indonesia, Southeast Asia’s largest pharmaceutical market, for its Enoxaparin in pre-filled syringes across all major strengths. This...
51-52, Industrial Area Phase-1, Panchkula, Haryana, 134113

+91-172-2933090, 2933094